OCA-B PEPTIDE INHIBITORS FOR THE TREATMENT OF TYPE-1 DIABETES

THERAPEUTICS

OCA-B peptide inhibitor that blocks autoimmunity preserving pancreatic β-cell functionality to provide long-term therapeutic benefit in T1D and Multiple Sclerosis.

TECHNOLOGY TYPE
Peptide
Type-1 Diabetes
Autoimmunity

STAGE OF DEVELOPMENT
- Proof of concept established through testing in NOD mice with T1D onset.
- Ongoing studies for peptide characterization and safety.

IP PROTECTION
Provisional Patent Filed

FEATURES AND BENEFITS
• Provides cell-permeable peptide inhibitor for T1D treatment.
• Decreases reliance on external insulin therapy with preservation of pancreatic β-cells.
• Reduces side effects by lowering pathogenic T-cell function in T1D.

RECENT PUBLICATIONS

INVENTOR PROFILE
Dean Tantin, Ph.D., Assistant and Associate Professor - Pathology

DATE UPDATED: 5/10/2018